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Abstract
Background: Inflammation is the main cause of disease-associated muscle wasting. In a previous single blind
study we have demonstrated improved recovery of muscle endurance following celecoxib treatment in
hospitalized geriatric patients with acute infection. Here we further evaluate NSAID treatment with piroxicam in a
double blind RCT and investigate the role of cytokines and heat shock proteins (Hsp) with respect to muscle
performance. We hypothesized that NSAID treatment would preserve muscle performance better than antibiotic
treatment alone, by reducing infection-associated inflammation and by increasing expression of cytoprotective Hsp.
Methods: Consecutive admissions to the geriatric ward were screened. 30 Caucasian patients, median age 84.5
years, with acute infection-induced inflammation and serum levels of CRP > 10 mg/L were included and
randomized to active treatment with 10 mg piroxicam daily or placebo. Assessment comprised general clinical and
biochemical parameters, 25 cytokines in serum, intra-and extracellular Hsp27 and Hsp70, Elderly Mobility Scale
(EMS) scores, grip strength (GS), fatigue resistance (FR) and lean body mass (LBM). Patients were evaluated until
discharge with a maximum of 3 weeks after treatment allocation.
Results: EMS scores, FR and grip work (GW), a measure taking into account GS and FR, significantly improved with
piroxicam, but not with placebo. Early decreases in IL-6 serum levels with piroxicam correlated with better muscle
performance at week 2. Basal expression of Hsp27 in monocytes without heat challenge (WHC) was positively
correlated with FR at baseline and significantly increased by treatment with piroxicam compared to placebo.
Profound modifications in the relationships between cytokines or Hsp and changes in muscle parameters were
observed in the piroxicam group.
Conclusions: Piroxicam improves clinically relevant measures of muscle performance and mobility in geriatric
patients hospitalized with acute infection-induced inflammation. Underlying mechanisms may include
modifications in the cytokine network and increases in monocytic expression of cytoprotective Hsp27.
Trial registration number: ISRCTN: ISRCTN96340690
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Sarcopenia, the age-related loss of muscle mass and per-
formance, is a major component of frailty [1]. It is aggra-
vated by acute disease-induced muscle wasting,
precipitating functional decline during and after hospita-
lization. Inflammation with its accompanying cytokine
production is seen as a predominant cause of muscle
wasting due to chronic or acute disease [2]. Previously,
we have shown that acute inflammation hinders the
recovery of muscle performance in geriatric hospitalized
patients [3] and in elderly elective surgery patients [4].
Besides treatment of the underlying acute disease, inter-
ventions able to reduce inflammation-related adverse
outcomes may be warranted. We have previously demon-
strated a better recovery of muscle endurance following
treatment with celecoxib, a cyclooxygenase(COX)-2
selective drug, in hospitalized geriatric patients with
acute infection [5]. However, in that study only a few
inflammatory mediators were studied. Non selective non
steroidal anti-inflammatory drugs (NSAID), including
piroxicam, have been shown to inhibit lipopolysaccharide
(LPS)-induced expression of cytokines involved in
macrophage activation and in the acute phase response,
while activating stress genes and increasing the expres-
sion of heat shock proteins (Hsp) [6]. Cell-protective
mechanisms, such as increased production of Hsp, are
blunted in muscle tissues of older patients [7]. In the pre-
sent placebo-controlled randomized controlled trial
(RCT) we investigated the effect of piroxicam on the evo-
lution of muscle performance and mobility in hospita-
lized geriatric patients with acute infection. A large set of
circulating cytokines and chemokines as well as intra-and
extra-cellular Hsp were measured. We hypothesized that
NSAID treatment would preserve muscle performance
by reducing infection-induced inflammation faster than
antibiotics alone, and possibly by increasing expression of
Hsp. Our results show improvements in muscle perfor-
mance and basic mobility with piroxicam, but not with
placebo.
Methods
Participants
Patients aged ≥ 70 years, consecutively admitted to an
acute geriatric ward of a general teaching hospital for
acute infection (documented by C-reactive protein (CRP)
serum level > 10 mg/L and/or fibrinogen > 400 mg/dL),
were eligible. Patients presenting inflammation of non-
infectious origin, using corticosteroids or NSAID within
the past seven days, or showing contra-indication to treat-
ment were excluded, as well as patients in a (pre)terminal
phase, bad general condition, dementia or confusion
severe enough to compromise the testing. The use of inha-
lation corticosteroids, low dose aspirin (as anti-aggregating
medication) and paracetamol was allowed. Patients were
included within 72 h after admission.
The study protocol was approved by the IRB and all
patients (or proxy) gave written informed consent. The
RCT was registered as ISRCTN58517443.
Intervention and treatment
Patients were randomized, using numbered containers, to
receive piroxicam 10 mg or placebo daily for ten days. All
patients, except those already using proton pump inhibi-
tors, also received oral ranitidine 150 mg daily to avoid
gastro-intestinal side effects. The medical staff was
blinded to treatment allocation and patients received
standard care. Patients were evaluated until discharge
with a maximum of 21 days after treatment allocation.
Measurements
Primary outcomes were changes in muscle mass, muscle
performance, mobility as evaluated by the Elderly Mobi-
lity Scale (EMS [8]), and evolution of cyto-/chemokines
and Hsp. Explanatory variables included type of infection,
comorbidity and general patient parameters such as age,
gender, height and weight, as well as basal activities of
daily living at admission (bADL; modified scale according
to Katz et al.) [9], pre-admission instrumental ADL
(iADL; 7-point Lawton scale) [10], and complete bio-
chemical and hematological profile, including renal func-
tion (Cockcroft & Gault formula) [11]. Safety outcomes
were evolution of renal function, side effects and
mortality.
Samples were taken at baseline, after 1, 2 and 3 days,
and after 1, 2 and 3 weeks. Peripheral venous blood was
collected in the morning after overnight fasting. Clini-
cally relevant parameters were immediately determined.
Serum was stored at -20°C for determination of cyto-/
chemokines and circulating Hsp. EDTA anticoagulated
blood was used for immediate determination of intracel-
lular Hsp in mononuclear cells. For technical reasons
intracellular Hsp was not determined on day 3.
Muscle performance: Grip strength, fatigue resistance and
grip work
Grip strength (GS) and fatigue resistance (FR) were mea-
sured within 72 h after admission using a Martin Vigori-
meter device (Elmed, Addison, USA) by specially trained
physiotherapists as previously described [12]. Briefly, the
patients were instructed to squeeze the rubber bulb of
the Vigorimeter as hard as possible, with the elbow flexed
at 90°. The best result of three trials for each hand was
recorded. The patients were then asked to maintain a
maximal pressure as long as possible, under repeated ver-
bal stimulations by the physiotherapist, and the time (in
seconds) until grip strength decreased to 50% of its maxi-
mum value was recorded for each hand. Grip work (GW)
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Page 2 of 12was calculated as reported previously [13]: GW =
(GSx0.75)xFR. For GS, FR and GW the mean values of
both hands were used.
Lean body mass
Lean body mass (LBM) was assessed by measuring natu-
rally occurring isotopic
40 K in a whole body counter.
40 K
represents 0.012% of total K and is the major source of
corporeal radioactivity. The whole body counter used
(Nuclear Enterprise, UK) consists of four 10 × 15 cm thal-
lium activated sodium iodine crystals, two above and two
beneath an examination bed of perspex. The detectors can
be moved along the axis XYZ to achieve the best counting
geometry. To keep the background as low as possible, the
detectors and examination bed are included in a closed
room built with steel from a boat sunken before the first
nuclear essays. The background is measured for 15 h the
night before the examination. The activity of the patient is
measured for 30 min in spectrometric mode; the back-
ground is subtracted and the
40 K peak (1.46 MeV) is
quantified. Four boxes each containing 500 g of KCl are
counted for 30 min in front of each detector. The
40 K
activities are summed for the reference samples and for
the patient, allowing to calculate the patient’s potassium
pool.
More than 95% of total body potassium is intracellu-
lar, found chiefly in muscle and viscera, and the potas-
sium pool is a good estimator of LBM [14]. LBM was
calculated as previously described [15] and expressed in
kg.
Cytokine determinations
Serum levels of 25 different cyto-/chemokines were mea-
sured simultaneously according to the manufacturer’s
indications (Multiplex Bead Immunoassay, Biosource
International, Nijvel, Belgium) including: IL-1b,I L - 1 R A ,
IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-
15, IL-17, CCL2/MCP-1, CCL3/MIP-1a,C C L 4 / M I P - 1 b,
CCL5/RANTES, CCL11/Eotaxin, CXCL8/IL-8, CXCL9/
MIG, CXCL10/IP-10, TNFa,I F N - a, IFN-g and GM-CSF
(for full names and sensitivities see legend of Table 1).
Sandwich ELISA for determination of RANTES and of hsp in
serum
RANTES levels were above detection limit with the
Multiplex Assay and were further analyzed using a com-
mercial ELISA kit (Invitrogen, Camarillo, USA). The
standard curve ranged from 0 to 2000 pg/mL (sensitivity
of 3 pg/ml).
Hsp27 and Hsp70 in serum were detected using com-
mercial ELISA kits (StressGen, Victoria, Canada). The
standard curve ranged from 0 to 12.5 ng/mL (sensitivity of
0.09 ng/ml) for Hsp70, and from 0 to 25 ng/ml (sensitivity
0.39 ng/ml) for Hsp27.
For both ELISA kits all reagents, dilutions and calcula-
tions were applied according to the manufacturer’s
instructions.
Flow cytometric determination of intracellular Hsp27 and
Hsp70
Hsp27 and Hsp70 were quantified in peripheral blood
cells using flow cytometry as previously reported [16].
Briefly, cells were incubated with anti-CD14 antibody
(Becton Dickinson, San Jose, Ca) for 15 min, washed in
PBS containing 1% BSA, and fixed in reagent A (IMTEC
Diagnostics, Antwerpen, Belgium) for 15 min. After
washing, the cells were permeabilized with reagent B
(IMTEC Diagnostics) and at the same time incubated
with the primary Hsp-specific antibody (clone G3.1,
SPA-800FI for Hsp27 and clone C92F3A-5, SPA-810 for
Hsp70; StressGen, Victoria, Canada). In negative con-
trols, an isotype matched goat IgG (Becton Dickinson,
San Jose, Ca) was used as the primary antibody. After
15 min incubation, cells were washed, and 500 μlo f
facsflow solution Becton Dickinson, San Jose, Ca) were
added in the case of Hsp27. For Hsp70 the labeled cells
were further re-suspended in reagent B and the second-
ary antibody (Goat anti-mouse gG, IMTEC Diagnostics),
and incubated for 15 min. Cells were washed and 500 μl
of Facsflow solution were added. The samples were ana-
lyzed immediately or within a few hours (stored at 4°C)
using the flow cytometer Epics-XL-MLC.
Heat shock procedures
Intracellular Hsp levels were determined both with and
without heat challenge (HC and WHC respectively), at
room temperature, as previously described [17]. Briefly,
for HC, Petri dishes containing the cells were heated at
4 2 ° Cf o r1h .A f t e rH C ,a d h e r e n tc e l l sw e r ea l l o w e dt o
recover for 16 h at 37°C in a 5% CO2 incubator. Cells were
then detached, washed, counted, and their viability
assessed. At least 85% of the cells survived after exposure
to 42°C for 1 h.
Statistical analysis
Analyses were done using IBM SPSS statistics 19.0 (SPSS
Inc, Illinois, USA). Data are reported as median ± inter-
quartile range. As several datasets for muscle performance
and cytokines were not normally distributed non-para-
metric procedures (with exact testing) were used: Spear-
man’s rho for correlations, Mann Whitney U test for
unpaired comparisons, Friedman test for overall time
effects, and Wilcoxon’s signed rank test for changes rela-
tive to baseline. Differences in the patterns of relationships
between changes in cytokines during hospitalization were
analyzed using the McNemar test. Differences in propor-
tions were analyzed using the Pearson Chi-square test. Sig-
nificance was set a priori at two-sided p < 0.05.
Results
General characteristics
30 Caucasian patients, median age 84.5 years (range 70-
94), were included (see Figure 1). One patient in each
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zation, and no follow-up evaluation of the primary out-
come measures was possible (one patient with rapidly
improving respiratory infection in the piroxicam group
was discharged from the hospital on his demand; one
patient with epileptic seizures in the placebo group was
withdrawn from the study). As shown in Table 1 and 2, no
significant differences were observed at baseline between
the two treatment groups. Patients were predominantly
female, highly dependent in bADL and iADL, a majority
(21 patients) was malnourished (based on serum prealbu-
min < 0.20 g/dL), had a moderately reduced renal function
and showed multiple comorbidity.
No significant gender difference was observed for GS,
FR or GW. GS tended to be lower in women (p =0 . 0 6 8 ) .
After correcting GS for body weight, this tendency disap-
peared. Data from men and women were pooled and all
analyses were done for GS, FR and GW per kg body
weight. Women had higher baseline levels of CRP than
men (p = 0.022), but the proportion of women was the
same in both groups and no differences in serum CRP
levels were observed between treatment groups for
women and men respectively. CRP decreased signifi-
cantly in both treatment groups (p < 0.001 for placebo
and for piroxicam at weeks 1, 2 and 3). LBM was mea-
sured in 24 of the 28 follow-up patients. Four patients,
two in each treatment arm, could not be evaluated having
undergone other nuclear medicine examinations.
Throughout the study, IL-5, IL-13, IL-17 and IFNg levels
remained below the detection limit in more than 70% of
the patients in both groups. Further analyses thus con-
cerned the remaining 21 cyto-/chemokines.
Changes in mobility and muscle performance over time
During follow-up EMS scores improved significantly after
two weeks with piroxicam (p = 0.021), with a positive
Table 1 Participants’ baseline characteristics
Placebo N = 14 Piroxicam N = 14
General characteristics
Age, years 82.5 (79.5-86.5) 85.0 (76.8-91.0)
Gender, number (%) female 10 (71.4%) 9 (64.3%)
BMI, kg/m
2 23.6 (18.3-26.3) 26.2 (20.1-28.2)
Proportion BMI < 20 4 (28.6%) 2 (14.3%)
Proportion BMI > 25 5 (35.7%) 8 (57.1%)
bADL, 24 point Katz scale 18.0 (10.3-20.3) 12.0 (9.5-19.5)
iADL, 7 point Lawton scale 1.5 (0.3-3.5) 2.0 (1.0-4.0)
EMS, 20 point scale 5.5 (1.0-8.0) 2.5 (0.0-8.5)
Type of infection & comorbidity
- Respiratory, number 8 (57.1%) 6 (42.9%)
- Urinary, number 1 (7.1%) 4 (28.6%)
- Gastro-intestinal, number 3 (21.4%) 1 (7.1%)
Other, number 2 (14.3%) 3 (21.4%)
Number of diagnoses 7.0 (4.8-10.3) 8.0 (5.5-11.0)
Biochemical parameters
CRP, mg/L 89.0 (40.5-156.3) 78.0 (29.8-235.3)
Fibrinogen, mg/dL 651.0 (489.3-752.5) 594.0 (482.5-710.0)
Hb, g/dL 12.7 (11.9-13.8) 12.1 (10.5-13.7)
Prealbumin, g/dL 0.14 (0.09-0.17) 0.14 (0.10-0.18)
GFR, mL/min 54.9 (38.4-65.5) 47.3 (31.6-56.4)
Skeletal muscle evaluations
GS*/body weight (kPa/kg) 0.24 (0.11-0.43) 0.44 (0.24-0.63)
FR*/body weight (sec/kg) 0.21 (0.03-0.54) 0.37 (0.21-0.78)
GW*/body weight (kPa × sec/kg) 3.1 (0.1-8.2) 7.5 (2.7-17.5)
LBM (kg) 24.0 (17.9-30.6) 26.1 (24.9-30.3)
Data represent median values (interquartile range) for continuous variables and numbers (percentage) for categorical variables. No significant difference was
observed for any of the parameters.
BMI = body mass index. bADL = basic activities of daily living. iADL = instrumental activities of daily living. CRP = C-reactive protein. Hb = hemoglobin. GFR =
glomerular filtration rate calculated with the Cockcroft & Gault formula. GS = grip strength. FR = fatigue resistance. GW = grip work. LBM = lean body mass. *
(mean of both hands).
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positive tendency was observed in the placebo group at
week 2 and no effect at week 3 (p = 0.054 and p = 0.565
respectively). LBM and GS did not change significantly in
either group. FR increased in the piroxicam group. A sig-
nificant overall time effect was observed (p = 0.004, Fried-
man test over 3 week period), with a tendency for
improvement compared to baseline at week 2 and a signif-
icant change at week 3 (p = 0.059 and p = 0.018 respec-
tively, Wilcoxon’s signed rank test). GW also improved
with piroxicam. A significant overall time effect was
observed (p = 0.011, Friedman test over 3 week period),
with improvements at weeks 2 and 3 compared to baseline
(p =0 . 0 1 3a n dp = 0.028 respectively, Wilcoxon’ss i g n e d
rank test) (Figure 2). Body weight and LBM were corre-
lated at baseline (r = 0.902, p < 0.001, Spearman’sr h o ) .
Consequently, when correcting GS, FR and GW for LBM
instead of body weight, comparable results with the same
level of significance were observed (for GS: no significant
change; for FR: p = 0.004 for overall time effect, and
compared to baseline p = 0.074 and p = 0.018 at weeks 2
and 3 respectively; for GW: p = 0.011 for overall time
effect, and compared to baseline p = 0.013 and p =0 . 0 2 8
at week 2 and 3 respectively). FR and GW showed no
change in the placebo group. However, the changes in FR
or GW showed no significant difference between groups.
Relationships between baseline inflammation and
changes in muscle performance
Correlations between baseline levels of cytokines and
subsequent changes in muscle parameters were exclu-
sively negative in the placebo group and were positive in
the piroxicam group, except for IL-10, RANTES and
MIG. The cytokines that were correlated with changes in
muscle parameters differed largely between the treat-
ments groups (Figure 3a). Baseline Hsp27 WHC and
after HC showed multiple, exclusively negative correla-
tions with the evolution of GS, FR, GW and EMS in the
placebo group. In the piroxicam group Hsp27 WHC
showed positive correlations, and Hsp27 after HC
Eligible  (n=30)
Allocated to Piroxicam
(n=15)
Allocation
Follow-Up
&
Analysis 
Randomization
Stopped 1: early discharge
Day 7 (n=14)
Stopped 2: 1 death, 1 GI bleeding
Discharge 2
Day 14 (n=10)
Stopped 0
Discharge 2
Day 21 (n=8)
Allocated to Placebo
(n=15)
Stopped 1: epilepsia
Day 7 (n=14)
Stopped 1: non compliance
Discharge 0
Day 14 (n= 13)
Stopped 0
Discharge 2
Day 21 (n=11)
Figure 1 Flow chart. Numbers of patients at randomization, treatment allocation and each time point during follow-up.
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sensitivity Placebo N = 14 Piroxicam N = 14
Cytokines in pg/mL
IL-1beta < 15 31.0 (21.0-112.5) 14.9 (14.9-65.3)
IL-1RA < 20 245.0 (134.5-537.0) 412.0 (177.5-615.0)
IL-2 < 15 14.9 (14.9-35.0) 14.9 (14.9-14.9)
IL-2R < 40 248.0 (150.5-346.5) 427.5 (207.5-595.0)
IL-4 < 5 4.9 (4.9-22.5) 4.9 (4.9-10.5)
IL-5 < 5 LO LO
IL-6 < 5 22.0 (14.5-89.5) 19.0 (6.5-160.5)
IL-7 < 25 24.9 (24.9-32.5) 24.9 (24.9-40.5)
IL-10 < 3 5.0 (3.0-29.0) 5.0 (3.0-6.0)
IL-12 < 6 169.0 (107.0-253.0) 160.0 (115.0-274.3)
IL-13 < 6 LO LO
IL-15 < 25 39.0 (24.9-134.5) 25.0 (24.9-60.0)
IL-17 < 20 LO LO
GM-CSF < 5 4.9 (4.9-44.0) 4.9 (4.9-8.0)
TNF-alpha < 5 4.9 (4.9-9.5) 4.9 (4.9-8.5)
IFN-alpha < 25 38.0 (25.5-66.5) 41.5 (24.9-55.3)
IFN-gamma < 2 LO LO
MCP-1/CCL2 < 8 778.0 (561.0-1228.5) 818.0 (458.5-1017.0)
MIP-1alpha/CCL3 < 15 44.0 (21.5-96.5) 49.0 (30.0-66.5)
MIP-1beta/CCL4 < 10 123.0 (62.0-186.0) 106.0 (56.0-192.0)
RANTES/CCL5 < 20 HI HI
Eotaxin/CCL11 < 5 76.0 (64.5-155.5) 79.0 (63.8-127.5)
IL-8/CXCL8 < 3 132.0 (60.0-294.5) 63.0 (53.5-276.0)
MIG/CXCL9 < 20 76.0 (61.0-186.0) 133.0 (82.0-180.5)
IP-10/CXCL10 < 5 44.0 (32.0-65.0) 53.0 (46.0-106.0)
Serum Hsp, ng/mL
- Hsp27 < 0.39 48.9 (14.3-72.3) 20.1 (15.8-53.5)
- Hsp70 < 0.09 1.1 (0.6-1.7) 1.5 (0.9-1.7)
Intracellular Hsp, MFI (flow cytometry)
- Hsp27
Lymphocytes - WHC 2.4 (1.6-4.3) 2.4 (1.5-4.9)
- 42°C (HC) 5.2 (3.4-7.6) 5.0 (4.1-6.5)
Monocytes - WHC 28.1 (25.3-42.9) 29.0 (16.0-43.1)
- 42°C (HC) 40.3 (29.2-51.2) 41.2 (29.8-59.9)
- Hsp70
Lymphocytes - WHC 2.1 (1.6-4.4) 2.5 (1.5-4.3)
- 42°C (HC) 11.9 (7.8-14.9) 13.5 (5.1-18.0)
Monocytes - WHC 13.5 (8.2-26.8) 12.7 (8.1-18.8)
- 42°C (HC) 244.1 (149.9-332.1) 211.0 (160.5-343.4)
Data represent median values (interquartile range). P-values refer to unpaired comparisons by Mann Whitney U test. No significant difference was observed for
any of the parameters. GM-CSF = granulocyte macrophage colony-stimulating factor; IL = interleukin. IL-1RA = IL-1 receptor antagonist. TNF-alpha = tumor
necrosis factor alpha. IFN = interferon. IL-2R = IL- 2 receptor. For chemokines old and new names are indicated, separated by a forward slash; MCP = monocyte
chemoattractant protein. MIP = macrophage inflammatory protein. RANTES = Regulated upon Activation, Normal T-cell Expressed, and Secreted. MIG = monokine
induced by interferon gamma. IP-10 = interferon g-inducible protein 10. Hsp = heat shock protein(s), MFI = Mean Fluorescence Intensity, WHC = without heat
challenge, 42°C(HC) = heat challenge, LO = below lower detection limit, HI = above upper detection limit.
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Page 6 of 12negative correlations. Hsp70 WHC and after HC showed
several negative correlations in the piroxicam group and
a positive correlation in the placebo group, realizing a
rather inversed pattern of relationships (Figure 3b).
Relationships between changes in inflammatory markers
and changes in muscle performance
When correlations were computed between changes
compared to baseline (Figure 4a), an overall difference
in the pattern of relationships was observed in the pir-
oxicam group compared to placebo. Whereas various
positive correlations between the changes of inflamma-
tory and muscle parameters occurred in the placebo
group, these correlations were negative in the piroxicam
group for GS and GW, and, although the relationships
for FR remained positive, they concerned other inflam-
matory parameters. The correlations in the piroxicam
group were mainly found for early observations.
With respect to Hsp, serum Hsp70 decreased (p =
0.024), whereas Hsp27 WHC in monocytes increased
(p = 0.016) in the piroxicam group. The changes com-
pared to baseline were significantly different between
groups for Hsp27 in monocytes (p = 0.021), but not for
serum Hsp70. Hsp70 WHC in monocytes decreased in
both groups (p = 0.047 for placebo and p = 0.028 for
piroxicam). Changes in Hsp were heterogeneously
related to the changes in muscle parameters (Figure 4b).
Changes in general parameters
Serum potassium significantly increased in both groups
over time and serum levels were comparable at each
time point. Prealbumin increased in both treatment
groups after 1 week (p =0 . 0 2 5p i r o x i c a ma n dp =0 . 0 3 4
placebo).
GFR did not change over the whole study period.
Nevertheless, a temporary decrease was observed at
week 1 compared to baseline in the piroxicam group
(p = 0.022) with a tendency for lower GFR compared to
placebo (p = 0.071). There was a tendency for a higher
incidence in side effects in the piroxicam group (p =
0.075), but no difference in overall clinical evolution,
length of stay or mortality (Table 3).
Discussion
In this cohort of frail geriatric patients hospitalized with
acute infection-induced inflammation we observed a bet-
ter recovery of mobility, assessed by EMS, that paralleled
a better recovery of muscle performance, evaluated by
fatigue resistance and grip work, in the patients rando-
mized to double blind controlled treatment with piroxi-
cam. These improvements were not related to LBM that
did not change significantly during the study period, as
evaluated by total body potassium. We have previously
shown that muscle function is impaired in geriatric hos-
pitalized patients with inflammation and that the
decreased muscle function was not explained by muscle
mass estimations using anthropometric measures [3]. We
further demonstrated that inflammatory patients did not
recover muscle strength and fatigue resistance during
Figure 2 a-b-c: Changes in GS, FR and GW at weeks 1, 2 and 3
with placebo and piroxicam respectively.
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Page 7 of 12hospitalization despite adequate treatment of the under-
lying condition and a significant decrease in inflamma-
tory markers. These observations hold true in the present
study where no significant improvement in muscle
function of inflammatory patients was observed in the
placebo group despite a significant decrease in CRP
serum levels, and where the increases in FR, GW and
mobility observed with piroxicam were not related to
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Figure 3 Spearman’s rho correlations between baseline serum levels of cytokines (Figure 3a) or baseline levels of extra-and intra-
cellular Hsp (Figure 3b) and subsequent changes in muscle parameters (raw data as well as results corrected by kg body weight and
by kg lean body mass). Significant correlations with p < 0.05 (two-sided) are indicated in red when positive, in blue when negative.
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Figure 4 Spearman’s rho correlations between changes in cytokines (Figure 4a) or changes in extra-and intra-cellular Hsp (Figure 4b)
and changes in muscle parameters (raw data as well as results corrected by kg body weight and by kg lean body mass). Significant
correlations with p < 0.05 (two-sided) are indicated in red when positive, in blue when negative. Serum levels of cytokines and Hsp were
measured at 6 follow-up time-points (changes to baseline indicated by 6 rectangles for each cytokine in each column). Intracellular Hsp were
measured at 5 follow-up time-points (changes to baseline indicated by 5 rectangles for each). Muscle parameters were evaluated at 3 follow-up
time-points. Correlations were computed between early changes (first days) in cytokines or Hsp and changes in muscle parameters at week 1
and 2. When correlations with these early changes were significant, white numbers in the corresponding rectangle indicate the corresponding
time-point of the concerned muscle parameter. The lower three rectangles indicate the concomitant changes compared to baseline at weeks 1,
2 and 3 for both parameters concerned.
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Muscle performance is difficult to evaluate in hospita-
lized geriatric patients. We previously developed a FR test
easy to use in frail geriatric patients in order to evaluate
muscle endurance [12]. This test has been able to detect
differences between inflammatory and non inflammatory
patients in the absence of changes in the classical GS test
that evaluates a brief maximal contraction [3]. GW that
integrates GS and FR probably is the most clinically rele-
vant measure, as it indicates the capacity of sustaining
strength in time, required by many activities of daily living
[4]. Correction for body weight takes into account that
physical efforts are determined not only by the action or
object itself, but also by a person’s own body weight.
Furthermore, it is important that these measures translate
into functional improvements. Here, we demonstrate sig-
nificant increases in FR and GW corrected for body weight
and EMS scores with piroxicam, but not with placebo. The
EMS measures basic mobility reflecting the capacity of our
acutely ill patients to get out of bed and move around. Not
only does this indicate better performance, but it also
reflects a decreased risk for the vicious cycle of acute weak-
ness and fatigue leading to immobility, disuse atrophy,
further weakness and functional decline.
Loss of muscle performance in our patients occurred in
the absence of significant loss of muscle mass. Skeletal
muscle contractility can be influenced by cytokines
directly, independent of changes in muscle mass and pro-
tein content. Monocyte inflammatory products released
during sepsis, especially TNFa, have been shown to impair
skeletal muscle contractility through an increase in mito-
chondrial or cytosolic production of reactive oxygen spe-
cies (ROS) [18], and calcium-activated calpains lead to Z
disk disruption and release of myofilaments, a phenom-
enon that has been shown to be up regulated in sepsis
[18]. In addition, cytokine-induced sickness behaviour and
fatigue, mediated by the central nervous system, probably
contribute to lower muscle endurance. Here, we investi-
gated the role of a large panel of cyto-/chemokines. Higher
baseline levels of several cyto-/chemokines were correlated
to worse evolution of muscle parameters in the placebo
group, and to better evolution in muscle function in the
piroxicam group, suggesting a more pronounced effect of
NSAID treatment when baseline inflammation is more
severe.
In a previous semi-blinded trial we showed that FR
improves significantly (> 60%) following treatment with a
selective COX-2 inhibitor [5], but cytokines were not fol-
lowed up during the first week. Here, we show that
changes in muscle parameters at week 1 and week 2 are
mainly correlated to early changes in cytokine levels dur-
ing the first days. Exclusively positive correlations in the
placebo group reflect decreases in cytokine levels that par-
allel decreases in muscle performance despite adequate
treatment of the infectious disease. With piroxicam, nega-
tive correlations indicate that decreases in cytokine levels
are related to improved muscle performance and it is
noteworthy that early decreases in IL-6 serum levels with
piroxicam were correlated with increased GW perfor-
mance at week 2. The persistence of positive correlations
between changes in cytokines and changes in FR are unex-
pected, but concern other cyto-/chemokines than in the
placebo group and may reflect immunomodulatory rather
than simply cytokine-inhibitory effects of piroxicam.
COX-specific effects of piroxicam [19] and immunomodu-
latory and COX-independent effects have been described
and discussed elsewhere, in general [20,21], and in this
patient cohort in particular [22].
NSAID treatment may partially induce the human heat
shock response [21]. In our patients basal expression of
Hsp27 in monocytes WHC, but stimulated by infection-
induced inflammation, was positively correlated with FR
and LBM at baseline and significantly increased by treat-
ment with piroxicam compared to placebo. Activation of
stress genes by NSAID, including piroxicam, has previously
Table 3 Clinical evolution
Placebo Piroxicam p
Clinical evolution (number of patients)
Return to premorbid
clinical status
6 10 0.127*
Persistent decrease in
clinical status
84
Side effects (attributable to NSAID)
None 13 8 0.075*
Possible 1 3
Probable 0 3
Length of stay (days; median, range) 24.5 (19-64) 29.0 (9-75) 0.836
†
Death 1 2 0.541*
*Pearson Chi square test.
†Mann Whitney U test.
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Page 10 of 12been described [6]. Hsp27 expression is abundant not only
in PBMC, but also in skeletal muscle; it has been shown to
increase with aging in muscle homogenate samples at rest
[23] and has been linked to improved cardiac muscle func-
tion after ischemic injury [24]. Hsp27 thus might play a
direct role in muscle protection in our patients if its
expression in PBMC is a good substitute for its expression
in myocytes. More invasive biopsy studies are required to
elucidate this hypothesis.
It cannot be excluded that some contrasts might have
been missed due to dropouts (thus increasing the risk for
a type-2 error in our study). The number of patients
recruited here was based on a sample size calculation
using data of a previous study demonstrating significant
effects of celecoxib on muscle endurance and mobility
within and between groups with the same sample size (n =
15 per group) [5]. Even though the mean length of stay
was 27 days in the geriatric ward where the present study
was carried out, our cohort suffered from losses due to
almost twice as many discharges before the scheduled fol-
low up at 3 weeks in the piroxicam group (46%) compared
to the placebo group (25%). The time of discharge was
decided independently of the study (by independent physi-
cians), and it might be possible that patients with an early
discharge presented with better recovery of muscle perfor-
mance and that significant between-group effects may
have been missed due to insufficient sample size. However,
the study design did neither include prolonged hospitaliza-
tion nor follow up evaluations after discharge. The latter
may be a relevant attention point for future study designs.
Nevertheless, the present sample size was sufficient to
detect significant within group improvements. Post hoc
power calculations indicated power > 80% for detecting
the observed changes (with alpha = 0.05) in EMS, FR and
GW in 15 patients over 3 weeks. For GS however, power
was lower (40%).
Conclusion
The present double blind RCT suggests a better initiation
of recovery in muscle endurance (FR and GW corrected
by body weight) and mobility with the COX non selective
NSAID piroxicam in geriatric patients hospitalized with
acute infection, and confirms our earlier findings in a sin-
gle blinded study with the COX-2 selective celecoxib.
Anti-inflammatory strategies in these patients deserve
more attention in clinical decision making, since grip
work capacity per kg body weight and mobility represent
clinically relevant outcomes with respect to performing
daily activities. Modulation of the cytokine network and
increases in cellular expression of Hsp27 appear to parti-
cipate in the underlying mechanisms that are favorably
influenced by treatment. The safety profile of piroxicam
appears acceptable when associated with protection of
the gastric mucosa.
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